Prolonged endometrial stimulation associated with oestradiol implants
- PMID: 2107895
- PMCID: PMC1662234
- DOI: 10.1136/bmj.300.6722.436
Prolonged endometrial stimulation associated with oestradiol implants
Abstract
Objective: To provide information on endometrial stimulation after discontinuation of treatment with oestradiol implants.
Design: Long term follow up of withdrawal bleeding patterns in women taking progestogens cyclically every month after oestradiol implant treatment was ended.
Setting: Specialist menopause clinic.
Subjects: 10 Postmenopausal patients (at least 12 months' amenorrhoea after the last spontaneous period) who were treated with oestradiol implants for typical symptoms of oestrogen deficiency. The oestradiol dose was 50 mg, reimplantation occurring roughly every six months. Patients subsequently either needed to discontinue the hormone treatment for medical reasons or expressed a desire to stop treatment.
Main outcome measure: Duration of endometrial stimulation--defined as the presence of withdrawal bleeding in response to progestogen given cyclically--after insertion of the last oestradiol implant.
Results: Four patients eventually stopped bleeding, their mean duration of bleeding being 35 months (range 27-43 months). One patient required hysterectomy 26 months after the last implantation because of persistent irregular bleeding despite treatment with high doses of progestogen. Three patients bled for 22, 30, and 36 months and then restarted oestrogen treatment because symptoms returned. The last two patients subsequently continued to bleed 12 and 21 months after the last implantation.
Conclusions: The duration of endometrial stimulation after implantation can be prolonged, up to 43 months. Insertion of oestradiol implants can carry a long term commitment to the cyclical administration of progestogen and regular withdrawal bleeding if endometrial hyperplasia and carcinoma are to be avoided.
Similar articles
-
Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.BMJ. 2002 Aug 3;325(7358):239. doi: 10.1136/bmj.325.7358.239. BMJ. 2002. PMID: 12153918 Free PMC article.
-
Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.Br J Obstet Gynaecol. 1997 Oct;104(10):1184-90. doi: 10.1111/j.1471-0528.1997.tb10944.x. Br J Obstet Gynaecol. 1997. PMID: 9332998
-
A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol.Br J Obstet Gynaecol. 1995 Mar;102(3):243-8. doi: 10.1111/j.1471-0528.1995.tb09102.x. Br J Obstet Gynaecol. 1995. PMID: 7794851 Clinical Trial.
-
Endometrial morphology and bleeding patterns as a function of progestogen supplementation.Int J Fertil Menopausal Stud. 1996 Jan-Feb;41(1):22-8. Int J Fertil Menopausal Stud. 1996. PMID: 8673153 Review.
-
Bleeding with menopausal hormone therapy: physiological or pathological?Menopause Int. 2007 Dec;13(4):188-90. doi: 10.1258/175404507783004005. Menopause Int. 2007. PMID: 18088532 Review.
Cited by
-
Hormone replacement therapy in the aged. A state of the art review.Drugs Aging. 1996 Mar;8(3):193-213. doi: 10.2165/00002512-199608030-00005. Drugs Aging. 1996. PMID: 8720745 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources